Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Sarosy

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Seminars in Oncology|February 1, 1989
Ifosfamide--pharmacologic overviewG Sarosy
Journal of the National Medical Association|June 1, 1993
Taxol dose intensification and its clinical implicationsG Sarosy, E Reed
The Journal of Infusional Chemotherapy|January 1, 1996
Paclitaxel dose intensityE Reed, R Bitton, G Sarosy, et al.
Hematology/Oncology Clinics of North America|March 18, 1999
Future directions with taxane therapyF Cabral, E Trimble, E Reed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1988
The systemic administration of intravenous melphalanG Sarosy, B Leyland-Jones, P Soochan, et al.
The American Journal of Medicine|August 1, 1996
Borderline ovarian tumorsC J Link, E Reed, G Sarosy, et al.
Annals of Internal Medicine|January 1, 1989
Autologous bone marrow transplantation. Current status and future directionsB D Cheson, L Lacerna, B Leyland-Jones, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
Synchronous inflammatory breast cancer and advanced ovarian carcinoma: a case with prolonged disease-free survivalV Sandor, E Reed, G Sarosy, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Anthracycline analogs: the past, present, and futureR B Weiss, G Sarosy, K Clagett-Carr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1988
N-methylformamide: cytotoxic, radiosensitizer, or chemosensitizerK Clagett-Carr, G Sarosy, J Plowman, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Seminars in Oncology|February 1, 1989
Ifosfamide--pharmacologic overviewG Sarosy
Journal of the National Medical Association|June 1, 1993
Taxol dose intensification and its clinical implicationsG Sarosy, E Reed
The Journal of Infusional Chemotherapy|January 1, 1996
Paclitaxel dose intensityE Reed, R Bitton, G Sarosy, et al.
Hematology/Oncology Clinics of North America|March 18, 1999
Future directions with taxane therapyF Cabral, E Trimble, E Reed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1988
The systemic administration of intravenous melphalanG Sarosy, B Leyland-Jones, P Soochan, et al.
The American Journal of Medicine|August 1, 1996
Borderline ovarian tumorsC J Link, E Reed, G Sarosy, et al.
Annals of Internal Medicine|January 1, 1989
Autologous bone marrow transplantation. Current status and future directionsB D Cheson, L Lacerna, B Leyland-Jones, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 23, 1999
Synchronous inflammatory breast cancer and advanced ovarian carcinoma: a case with prolonged disease-free survivalV Sandor, E Reed, G Sarosy, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Anthracycline analogs: the past, present, and futureR B Weiss, G Sarosy, K Clagett-Carr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1988
N-methylformamide: cytotoxic, radiosensitizer, or chemosensitizerK Clagett-Carr, G Sarosy, J Plowman, et al.
Pageof 3